Literature DB >> 29093101

VP1 and VP3 Are Required and Sufficient for Translation Initiation of Uncapped Infectious Bursal Disease Virus Genomic Double-Stranded RNA.

Chengjin Ye1, Yu Wang1, Enli Zhang1, Xinpeng Han1, Zhaoli Yu1, Hebin Liu2,3.   

Abstract

Infectious bursal disease virus (IBDV) is a bisegmented double-strand RNA (dsRNA) virus of the Birnaviridae family. While IBDV genomic dsRNA lacks a 5' cap, the means by which the uncapped IBDV genomic RNA is translated effectively is unknown. In this study, we describe a cap-independent pathway of translation initiation of IBDV uncapped RNA that relies on VP1 and VP3. We show that neither purified IBDV genomic dsRNA nor the uncapped viral plus-sense RNA transcripts were directly translated and rescued into infectious viruses in host cells. This defect in translation of the uncapped IBDV genomic dsRNA was rescued by trans-supplementation of the viral proteins VP1 and VP3 which was dependent on both the intact polymerase activity of VP1 and the dsRNA binding activity of VP3. Deletion analysis showed that both 5' and 3' untranslated regions (UTRs) of IBDV dsRNA were essential for VP1/VP3-dependent translation initiation. Significantly, VP1 and VP3 could also mediate the recovery of infectious IBDV from the authentic minus-sense strand of IBDV dsRNA. Moreover, downregulation or inhibition of the cap-binding protein eIF4E did not decrease but, rather, enhanced the VP1/VP3-mediated translation of the uncapped IBDV RNA. Collectively, our findings for the first time reveal that VP1 and VP3 compensate for the deficiency of the 5' cap and replace eIF4E to confer upon the uncapped IBDV RNA the ability to be translated and rescued into infectious viruses.IMPORTANCE A key point of control for virus replication is viral translation initiation. The current study shows that the uncapped IBDV RNA cannot be translated into viral proteins directly by host translation machinery and is thus noninfectious. Our results constitute the first direct experimental evidence that VP1 and VP3 are required and sufficient to initiate translation of uncapped IBDV genomic RNA by acting as a substitute for cap and replacing the cap-binding protein eIF4E. Significantly, VP1/VP3 mediate the recovery of infectious IBDV not only from the plus-sense strand but also from the minus-sense strand of the IBDV dsRNA. These findings provide not only new insights into the molecular mechanisms of the life cycle of IBDV but also a new tool for an alternative strategy for the recovery of IBDV from both the plus- and the minus-sense strands of the viral genomic dsRNA.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  IBDV; double-strand RNA; infectious RNA; reverse genetics

Mesh:

Substances:

Year:  2018        PMID: 29093101      PMCID: PMC5752939          DOI: 10.1128/JVI.01345-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Activation mechanism of a noncanonical RNA-dependent RNA polymerase.

Authors:  Damià Garriga; Aitor Navarro; Jordi Querol-Audí; Fernando Abaitua; José F Rodríguez; Núria Verdaguer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

2.  RIG-I detects viral genomic RNA during negative-strand RNA virus infection.

Authors:  Jan Rehwinkel; Choon Ping Tan; Delphine Goubau; Oliver Schulz; Andreas Pichlmair; Katja Bier; Nicole Robb; Frank Vreede; Wendy Barclay; Ervin Fodor; Caetano Reis e Sousa
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

Review 3.  Regulation Mechanisms of Viral IRES-Driven Translation.

Authors:  Kuo-Ming Lee; Chi-Jene Chen; Shin-Ru Shih
Journal:  Trends Microbiol       Date:  2017-02-24       Impact factor: 17.079

Review 4.  Infectious bursal disease virus of chickens: pathogenesis and immunosuppression.

Authors:  J M Sharma; I J Kim; S Rautenschlein; H Y Yeh
Journal:  Dev Comp Immunol       Date:  2000 Mar-Apr       Impact factor: 3.636

5.  Evidence that the genomic RNA of hepatitis E virus is capped.

Authors:  Y Kabrane-Lazizi; X J Meng; R H Purcell; S U Emerson
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Characteristics and serologic studies of two serotypes of infectious bursal disease virus in turkeys.

Authors:  D J Jackwood; Y M Saif; J H Hughes
Journal:  Avian Dis       Date:  1982 Oct-Dec       Impact factor: 1.577

7.  The VP5 protein of infectious bursal disease virus promotes virion release from infected cells and is not involved in cell death.

Authors:  Yongping Wu; Lianlian Hong; Juxiu Ye; Zhenyu Huang; Jiyong Zhou
Journal:  Arch Virol       Date:  2009-10-20       Impact factor: 2.574

8.  Self-guanylylation of birnavirus VP1 does not require an intact polymerase activity site.

Authors:  Junhua Pan; Li Lin; Yizhi Jane Tao
Journal:  Virology       Date:  2009-10-04       Impact factor: 3.616

9.  The infectious bursal disease virus RNA-binding VP3 polypeptide inhibits PKR-mediated apoptosis.

Authors:  Idoia Busnadiego; Ana M Maestre; Dolores Rodríguez; José F Rodríguez
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Rescue of infectious birnavirus from recombinant ribonucleoprotein complexes.

Authors:  Romy M Dalton; José F Rodríguez
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more
  9 in total

Review 1.  Role of MicroRNAs in Host Defense against Infectious Bursal Disease Virus (IBDV) Infection: A Hidden Front Line.

Authors:  Jiaxin Li; Shijun J Zheng
Journal:  Viruses       Date:  2020-05-14       Impact factor: 5.048

2.  Ubiquitination Is Essential for Avibirnavirus Replication by Supporting VP1 Polymerase Activity.

Authors:  Huansheng Wu; Liuyuan Shi; Yina Zhang; Xiran Peng; Tuyuan Zheng; Yahui Li; Boli Hu; Xiaojuan Zheng; Jiyong Zhou
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 3.  Current Findings on Gut Microbiota Mediated Immune Modulation against Viral Diseases in Chicken.

Authors:  Muhammad Abaidullah; Shuwei Peng; Muhammad Kamran; Xu Song; Zhongqiong Yin
Journal:  Viruses       Date:  2019-07-25       Impact factor: 5.048

4.  Chicken eEF1α is a Critical Factor for the Polymerase Complex Activity of Very Virulent Infectious Bursal Disease Virus.

Authors:  Bo Yang; Nana Yan; Aijing Liu; Yue Li; Zehua Chen; Li Gao; Xiaole Qi; Yulong Gao; Changjun Liu; Yanping Zhang; Hongyu Cui; Kai Li; Qing Pan; Yongqiang Wang; Xiaomei Wang
Journal:  Viruses       Date:  2020-02-23       Impact factor: 5.048

5.  Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus.

Authors:  Yulong Wang; Nan Jiang; Linjin Fan; Li Gao; Kai Li; Yulong Gao; Xinxin Niu; Wenying Zhang; Hongyu Cui; Aijing Liu; Qing Pan; Changjun Liu; Yanping Zhang; Xiaomei Wang; Xiaole Qi
Journal:  Vaccines (Basel)       Date:  2021-02-10

6.  Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.

Authors:  Vishwanatha R A P Reddy; Salik Nazki; Andrew J Brodrick; Amin Asfor; Joanna Urbaniec; Yasmin Morris; Andrew J Broadbent
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

Review 7.  Synthesis and Translation of Viral mRNA in Reovirus-Infected Cells: Progress and Remaining Questions.

Authors:  Guy Lemay
Journal:  Viruses       Date:  2018-11-27       Impact factor: 5.048

8.  The Novel Genetic Background of Infectious Bursal Disease Virus Strains Emerging from the Action of Positive Selection.

Authors:  Anna Pikuła; Anna Lisowska; Agnieszka Jasik; Lester J Perez
Journal:  Viruses       Date:  2021-03-02       Impact factor: 5.048

9.  Identification and Pathogenicity Evaluation of a Novel Reassortant Infectious Bursal Disease Virus (Genotype A2dB3).

Authors:  Yulong Wang; Nan Jiang; Linjin Fan; Xinxin Niu; Wenying Zhang; Mengmeng Huang; Li Gao; Kai Li; Yulong Gao; Changjun Liu; Hongyu Cui; Aijing Liu; Qing Pan; Yanping Zhang; Xiaomei Wang; Xiaole Qi
Journal:  Viruses       Date:  2021-08-25       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.